Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.82 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.68 |
| ▸ | USP2 | O75604 | 2/20 | 0.68 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.66 |
| ▸ | MAPT | P10636 | 4/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 2/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15551249 | 0.93 | RAB9A (0.91) | RAB9AALDH1A1USP2L3MBTL1MAPT | |
| SCHEMBL14142894 | 0.88 | ALDH1A1 (0.87) | RAB9AALDH1A1USP2L3MBTL1MAPT | |
| SCHEMBL13401886 | 0.87 | ALDH1A1 (0.65) | RAB9AALDH1A1USP2L3MBTL1MAPT | |
| SCHEMBL19334435 | 0.87 | RAB9A (0.73) | RAB9AALDH1A1L3MBTL1MAPTMEN1 | |
| SCHEMBL13401903 | 0.87 | TAAR1 (0.72) | RAB9AALDH1A1L3MBTL1MAPTMAPK1 | |
| SCHEMBL625181 | 0.85 | ALDH1A1 (0.84) | RAB9AALDH1A1L3MBTL1MAPTMEN1 | |
| SCHEMBL14135605 | 0.81 | ALDH1A1 (0.71) | RAB9AALDH1A1USP2L3MBTL1MAPT | |
| SCHEMBL15679869 | 0.81 | PLAAT3 (0.73) | RAB9AL3MBTL1KMT2ASMN1; SMN2 | |
| SCHEMBL8628832 | 0.80 | ALDH1A1 (0.90) | RAB9AALDH1A1USP2L3MBTL1MAPT | |
| SCHEMBL13401887 | 0.80 | HTT (0.68) | RAB9AALDH1A1USP2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180110746-A1 | SMALL MOLECULE INHIBITORS OF TLR2 SIGNALING | UNIVERSITY OF MARYLAND, BALTIMORE | 2018-04-26 | — | — | US | disclosed |
| US-20180110746-A1 | SMALL MOLECULE INHIBITORS OF TLR2 SIGNALING | UNIVERSITY OF MARYLAND, BALTIMORE | 2018-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180110746-A1 | SMALL MOLECULE INHIBITORS OF TLR2 SIGNALING | TLR2, TLR1, TLR6 | RAB9A 4467/4885ALDH1A1 2824/4885USP2 3084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.